Thus, we suggest that HDAC inhibitors may function by modulating death receptor expression (e.g., DR5) in cancer cells and enhance their sensitivity to players in extrinsic apoptotic pathways (e.g., TRAIL). Here, TNFRSF10B is linked to cancer.